Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_assertion type Assertion NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_head.
- NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_assertion description "[Twenty-three patients with EGFR mutations received gefitinib, with an overall response rate (partial response [PR]) of 54.5% and disease control rate (PR + stable disease) of 86.4% (Response Evaluation Criteria in Solid Tumors).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_provenance.
- NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_assertion evidence source_evidence_literature NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_provenance.
- NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_assertion SIO_000772 21527506 NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_provenance.
- NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_assertion wasDerivedFrom befree-2016 NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_provenance.
- NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_assertion wasGeneratedBy ECO_0000203 NP890240.RAKfhbT9ZIcQ_g4yWHjeezZ2-fgXyEjf3wama8JzGcv6o130_provenance.